(b)(4).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported patient effects of thrombosis, ventricular tachycardia, and ventricular fibrillation are listed in the xience xpedition everolimus eluting coronary stent system instructions for use as known patient effects of coronary stenting procedures.Based on the information reviewed, there is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.
|
The procedure was to treat a lesion in the proximal left anterior descending coronary artery (lad).On (b)(6) 2016, a 3.5x38mm xience xpedition stent was implanted.On (b)(6) 2016, the patient presented with ventricular tachycardia, ventricular fibrillation, and cardiac arrest.Angiography confirmed in-stent thrombosis.A non-abbott device was used to suction the thrombosis and a 3.75x15mm nc trek and a 3.75x15mm non-abbott device were used to successfully finish the procedure.It was suspected that the patient had a plavix resistance and the patient was unconscious.There was no clinically significant delay in the procedure.No additionally information was provided.
|